AZP-3813 is being developed as a potential treatment for acromegaly to be used in combination with somatostatin analogues (SSAs) for patients who do not adequately respond to SSAs alone.

Acromegaly is a rare chronic endocrine disorder that is typically caused by an adenoma (benign tumor) of the pituitary gland and characterized by abnormally high levels of growth hormone (GH), secreted by the pituitary gland, which leads to excess production of IGF-1.

AZP-3813 was identified and optimized through a research collaboration with PeptiDream and is being developed as a potential next-generation GHRA therapeutic.

AZP-3813 Acromegal
Scroll to Top